ANTI PHOSPHOLIPID ANTIBODY (APL) - IGM

The antiphospholipid antibody test detects antibodies (anticardiolipin, lupus anticoagulant, anti–β2‑glycoprotein I) that raise the risk of abnormal clotting and pregnancy loss. It’s used for unexplained venous or arterial clots, recurrent miscarriages, young-stroke evaluation, or abnormal clotting screens. Positive results should be repeated after 12 weeks to confirm persistent antibodies and diagnose antiphospholipid syndrome.

aPL positive means a blood test has detected antiphospholipid antibodies (such as anticardiolipin, anti–β2‑glycoprotein I, or lupus anticoagulant). This can raise the risk of blood clots and pregnancy complications like recurrent miscarriage. Antibodies may be transient (after infection) or persistent; confirming antiphospholipid syndrome requires repeat testing at least 12 weeks later. Management depends on symptoms and clot risk.

The APA IgM test detects IgM-class antiphospholipid antibodies (anticardiolipin IgM and anti‑beta2 glycoprotein I IgM) in blood. Positive results may indicate antiphospholipid syndrome, raising risk of blood clots and pregnancy loss. It’s interpreted with clinical history and usually repeated after 12 weeks to confirm persistence. Results inform anticoagulation and pregnancy management decisions.

For antiphospholipid IgM (anticardiolipin or anti–β2 glycoprotein I) the usual laboratory reference: negative <20 units (MPL or U), borderline 20–40 units, and positive >40 units or above the 99th percentile. Clinical significance requires persistent positivity on repeat testing at least 12 weeks apart.

Yes. Antiphospholipid (aPL) antibodies — such as lupus anticoagulant, anticardiolipin, and anti‑β2‑glycoprotein I — can cause blood clots. Persistent aPL defines antiphospholipid syndrome, which raises risk of arterial and venous thrombosis and pregnancy loss. aPL antibodies promote clotting by disrupting anticoagulant pathways and activating endothelium, platelets and complement; diagnosis needs repeat testing and often anticoagulation.

APLA positivity raises the risk of blood clots and pregnancy complications (recurrent miscarriage, stillbirth, preeclampsia). Repeat testing after 12 weeks is needed to confirm persistence. Management depends on symptoms: asymptomatic people may be monitored; those with thrombosis or pregnancy often need specialist-directed anticoagulation or low‑dose aspirin and close obstetric care. Lifestyle changes and evaluation for autoimmune disease are recommended.